The management of invasive lobular breast cancer is evolving
Advances in molecular profiling and a greater understanding of the underlying biology are reinforcing the concept of a distinct disease from other ER-positive breast cancers
Liquid biopsy has the potential to improve patients’ lives across the entire spectrum of breast cancer
The 2026 ESMO Breast Cancer Awardee, Daniel F. Hayes, reflects on the future of biomarker research in the field
Why AI-powered trial matching alone will not fix oncology trial recruitment
AI-powered trial matching helps identify relevant trials faster, but recruitment often fails beyond the algorithm. Limited cross-site trial discovery, outdated recruitment information and fragmented referral pathways continue to prevent potentially eligible patients from participating in relevant trials.
Counting lines of therapy counts: ESMO leads the way of standardisation
A new ESMO consensus-driven document provides definitions, formats and minimum required data to uniform enumeration and reporting of prior lines of therapy across solid tumours
Novel emerging targets, new treatment opportunities
Drug development in oncology is increasingly moving towards integrated strategies that consider tumour cells, their microenvironment and anatomical context
Rare cancer patients still have limited access to personalised care in Europe
Despite advances in molecular profiling, only a small fraction of patients with actionable alterations receive matched targeted therapies or immunotherapies
Overcoming resistance to immunotherapy in NSCLC?
Understanding the evolution of immunotherapy resistance holds the key to developing novel strategies in NSCLC
Optimising cancer care to improve clinical outcomes and sustainability
From chronotherapy to immunotherapy resistance, refining when and for whom treatments work is becoming central to making oncology sustainable
A multimodal next-generation approach for early detection and risk stratification in lung cancer
Combining the optimisation of clinical pathways with tumour molecular insights enables more accurate and personalised cancer care
A visionary in lung oncology: the scientific and human legacy of Prof. Filippo de Marinis
A tribute from one of his former mentees, now a senior oncologist, on the occasion of the 2026 Heine H. Hansen Award presented to de Marinis